Several antitumor immune induction regimens are possible, including low-dose rhythm cyclophosphamide, high-dose COX-2 inhibitors, granulocyte colony-stimulating factor, sulfhydryl donors, and blood derivatives containing autologous tumor antigens released into the blood from the patient’s tumor. The gene discussed is CSF3; the disease is neoplasm.